Humulin R (Regolare)

Humulin R (Regolare) is a human insulin (rDNA) injection solution that is supplied in a standard concentration for subcutaneous, intramuscular, or intravenous use. It is a prescription‑only product marketed in the European Union and belongs to the antidiabetic drug class. The formulation provides rapid‑acting insulin to help regulate blood glucose levels in people with diabetes.

Humulin R is indicated for the management of blood glucose in diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other medications.

- Treatment of type 1 diabetes mellitus in adults, adolescents, and children. - Treatment of type 2 diabetes mellitus when rapid‑acting insulin is required. - Supplemental insulin for patients on basal insulin regimens. - Management of hyperglycemia during surgery or acute illness. - Use in insulin pump therapy where rapid‑acting insulin is needed. - Adjusted dosing for patients with variable carbohydrate intake.

Adverse reactions to Humulin R can vary in frequency and severity.

Common: - Hypoglycemia (low blood glucose) - Injection‑site pain, redness, or swelling - Weight gain - Lipodystrophy at injection sites - Mild allergic skin reactions

Serious: - Severe hypoglycemia leading to loss of consciousness - Anaphylactic or systemic allergic reactions - Acute insulin resistance - Persistent hyperglycemia due to antibody formation - Edema or heart failure exacerbation in susceptible patients

Humulin R should be used with careful monitoring and consideration of patient‑specific factors. - Adjust dose when renal or hepatic impairment is present. - Use caution in patients with cardiovascular disease or heart failure. - Monitor blood glucose closely during pregnancy, although safety data are limited. - Educate patients on recognizing and treating hypoglycemia. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Store the product according to label instructions to maintain potency.

Humulin R may interact with other medications, affecting glucose control or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment. - High‑dose beta‑blockers that may mask hypoglycemia symptoms. - MAO inhibitors that can potentiate insulin’s hypoglycemic effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which can raise blood glucose levels. - Diuretics, especially thiazides, that may affect glucose tolerance. - ACE inhibitors and ARBs, which may enhance insulin sensitivity. - Alcohol consumption, which can cause unpredictable glucose fluctuations.